Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy

Omar Ali El-Agnaf, Cassia Overk, Edward Rockenstein, Michael Mante, Jazmin Florio, Anthony Adame, Nishant Vaikath, Nour Majbour, Seung Jae Lee, Changyoun Kim, Eliezer Masliah, Robert A. Rissman

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Disorders with progressive accumulation of α-synuclein (α-syn) are a common cause of dementia and parkinsonism in the aging population. Accumulation and propagation of α-syn play a role in the pathogenesis of these disorders. Previous studies have shown that immunization with antibodies that recognize C-terminus of α-syn reduces the intra-neuronal accumulation of α-syn and related deficits in transgenic models of synucleinopathy. These studies employed antibodies that recognize epitopes within monomeric and aggregated α-syn that were generated through active immunization or administered via passive immunization. However, it is possible that more specific effects might be achieved with antibodies recognizing selective species of the α-syn aggregates. In this respect we recently developed antibodies that differentially recognized various oligomers (Syn-O1, -O2, and -O4) and fibrilar (Syn-F1 and -F2) forms of α-syn. For this purpose wild-type α-syn transgenic (line 61) mice were immunized with these 5 different antibodies and neuropathologically and biochemically analyzed to determine which was most effective at reducing α-syn accumulation and related deficits. We found that Syn-O1, -O4 and -F1 antibodies were most effective at reducing accumulation of α-syn oligomers in multiple brain regions and at preventing neurodegeneration. Together this study supports the notion that selective antibodies against α-syn might be suitable for development new treatments for synucleinopathies such as PD and DLB.

Original languageEnglish
Pages (from-to)85-96
Number of pages12
JournalNeurobiology of Disease
Volume104
DOIs
Publication statusPublished - 1 Aug 2017

Fingerprint

Synucleins
Immunotherapy
Antibodies
Passive Immunization
Parkinsonian Disorders
Dementia
Epitopes
Immunization
Vaccination
Brain

Keywords

  • Dementia with Lewy bodies
  • Fibrils
  • Oligomers
  • Parkinson's disease
  • Passive immunization
  • α-synuclein

ASJC Scopus subject areas

  • Neurology

Cite this

Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy. / Ali El-Agnaf, Omar; Overk, Cassia; Rockenstein, Edward; Mante, Michael; Florio, Jazmin; Adame, Anthony; Vaikath, Nishant; Majbour, Nour; Lee, Seung Jae; Kim, Changyoun; Masliah, Eliezer; Rissman, Robert A.

In: Neurobiology of Disease, Vol. 104, 01.08.2017, p. 85-96.

Research output: Contribution to journalArticle

Ali El-Agnaf, Omar ; Overk, Cassia ; Rockenstein, Edward ; Mante, Michael ; Florio, Jazmin ; Adame, Anthony ; Vaikath, Nishant ; Majbour, Nour ; Lee, Seung Jae ; Kim, Changyoun ; Masliah, Eliezer ; Rissman, Robert A. / Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy. In: Neurobiology of Disease. 2017 ; Vol. 104. pp. 85-96.
@article{538968cb659b4f0489ac347616e04e7f,
title = "Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy",
abstract = "Disorders with progressive accumulation of α-synuclein (α-syn) are a common cause of dementia and parkinsonism in the aging population. Accumulation and propagation of α-syn play a role in the pathogenesis of these disorders. Previous studies have shown that immunization with antibodies that recognize C-terminus of α-syn reduces the intra-neuronal accumulation of α-syn and related deficits in transgenic models of synucleinopathy. These studies employed antibodies that recognize epitopes within monomeric and aggregated α-syn that were generated through active immunization or administered via passive immunization. However, it is possible that more specific effects might be achieved with antibodies recognizing selective species of the α-syn aggregates. In this respect we recently developed antibodies that differentially recognized various oligomers (Syn-O1, -O2, and -O4) and fibrilar (Syn-F1 and -F2) forms of α-syn. For this purpose wild-type α-syn transgenic (line 61) mice were immunized with these 5 different antibodies and neuropathologically and biochemically analyzed to determine which was most effective at reducing α-syn accumulation and related deficits. We found that Syn-O1, -O4 and -F1 antibodies were most effective at reducing accumulation of α-syn oligomers in multiple brain regions and at preventing neurodegeneration. Together this study supports the notion that selective antibodies against α-syn might be suitable for development new treatments for synucleinopathies such as PD and DLB.",
keywords = "Dementia with Lewy bodies, Fibrils, Oligomers, Parkinson's disease, Passive immunization, α-synuclein",
author = "{Ali El-Agnaf}, Omar and Cassia Overk and Edward Rockenstein and Michael Mante and Jazmin Florio and Anthony Adame and Nishant Vaikath and Nour Majbour and Lee, {Seung Jae} and Changyoun Kim and Eliezer Masliah and Rissman, {Robert A.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.nbd.2017.05.002",
language = "English",
volume = "104",
pages = "85--96",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy

AU - Ali El-Agnaf, Omar

AU - Overk, Cassia

AU - Rockenstein, Edward

AU - Mante, Michael

AU - Florio, Jazmin

AU - Adame, Anthony

AU - Vaikath, Nishant

AU - Majbour, Nour

AU - Lee, Seung Jae

AU - Kim, Changyoun

AU - Masliah, Eliezer

AU - Rissman, Robert A.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Disorders with progressive accumulation of α-synuclein (α-syn) are a common cause of dementia and parkinsonism in the aging population. Accumulation and propagation of α-syn play a role in the pathogenesis of these disorders. Previous studies have shown that immunization with antibodies that recognize C-terminus of α-syn reduces the intra-neuronal accumulation of α-syn and related deficits in transgenic models of synucleinopathy. These studies employed antibodies that recognize epitopes within monomeric and aggregated α-syn that were generated through active immunization or administered via passive immunization. However, it is possible that more specific effects might be achieved with antibodies recognizing selective species of the α-syn aggregates. In this respect we recently developed antibodies that differentially recognized various oligomers (Syn-O1, -O2, and -O4) and fibrilar (Syn-F1 and -F2) forms of α-syn. For this purpose wild-type α-syn transgenic (line 61) mice were immunized with these 5 different antibodies and neuropathologically and biochemically analyzed to determine which was most effective at reducing α-syn accumulation and related deficits. We found that Syn-O1, -O4 and -F1 antibodies were most effective at reducing accumulation of α-syn oligomers in multiple brain regions and at preventing neurodegeneration. Together this study supports the notion that selective antibodies against α-syn might be suitable for development new treatments for synucleinopathies such as PD and DLB.

AB - Disorders with progressive accumulation of α-synuclein (α-syn) are a common cause of dementia and parkinsonism in the aging population. Accumulation and propagation of α-syn play a role in the pathogenesis of these disorders. Previous studies have shown that immunization with antibodies that recognize C-terminus of α-syn reduces the intra-neuronal accumulation of α-syn and related deficits in transgenic models of synucleinopathy. These studies employed antibodies that recognize epitopes within monomeric and aggregated α-syn that were generated through active immunization or administered via passive immunization. However, it is possible that more specific effects might be achieved with antibodies recognizing selective species of the α-syn aggregates. In this respect we recently developed antibodies that differentially recognized various oligomers (Syn-O1, -O2, and -O4) and fibrilar (Syn-F1 and -F2) forms of α-syn. For this purpose wild-type α-syn transgenic (line 61) mice were immunized with these 5 different antibodies and neuropathologically and biochemically analyzed to determine which was most effective at reducing α-syn accumulation and related deficits. We found that Syn-O1, -O4 and -F1 antibodies were most effective at reducing accumulation of α-syn oligomers in multiple brain regions and at preventing neurodegeneration. Together this study supports the notion that selective antibodies against α-syn might be suitable for development new treatments for synucleinopathies such as PD and DLB.

KW - Dementia with Lewy bodies

KW - Fibrils

KW - Oligomers

KW - Parkinson's disease

KW - Passive immunization

KW - α-synuclein

UR - http://www.scopus.com/inward/record.url?scp=85029902901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029902901&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2017.05.002

DO - 10.1016/j.nbd.2017.05.002

M3 - Article

VL - 104

SP - 85

EP - 96

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

ER -